Objectives: To examine the effects of chamuangone on human cancer cell proliferation, migration and apoptosis.
Methods: An MTT assay was used to study the effect of chamuangone on human cervical carcinoma cell growth. An in-vitro scratch migration assay was used to investigate the activity of cell motility after chamuangone treatment. Chamuangone-induced cell apoptosis in HeLa cells was determined using the apoptotic assay kit. The inhibitory activities of chamuangone were examined by ADP-Glo™ kinase assay. The GOLD docking algorithm was used to demonstrate the mechanism against tyrosine kinase of EGFR.
Key findings: Chamuangone showed a strong inhibitory cell proliferation of HeLa cells with IC50 values of 3.59 µm and effectively inhibited HeLa cell migration. In addition, chamuangone exhibited the apoptotic cell death induction in a time and dose-dependent manner. Finally, chamuangone also was tested for EGFR-TK inhibition activity. The IC50 value of chamuangone was 2.85 nm, whereas the IC50 value of gefitinib was 15.10 nm.
Conclusions: The above results confirm the inhibitory effects of chamuangone on HeLa cell proliferation and cell migration. In addition, chamuangone also induces cell apoptosis in HeLa cells. These findings indicate that chamuangone is a compound that is a potential chemotherapeutic agent.
Keywords: EGFR-TK; chamuangone; human cervical cancer cell; migration; proliferation.
© 2019 Royal Pharmaceutical Society.